Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms:

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 25 mg | $767 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $997 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $1,610 | 6-8 weeks | 6-8 weeks |
| Description | PKI-179 hydrochloride is a potent and orally available dual PI3K/mTOR inhibitor. Its IC₅₀ values against PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR are 8 nM, 24 nM, 74 nM, 77 nM and 0.42 nM respectively. It also exerts inhibitory activity against E545K and H1047R mutants with IC₅₀ values of 14 nM and 11 nM, and exhibits significant antitumor effects in in vivo models. |
| Targets & IC50 | PI3Kδ:77 nM, PI3Kβ:24 nM, PI3Kα:8 nM, mTOR:420 nM, PI3Kγ:74 nM, E545K:14 nM, H1047R:11 nM |
| In vitro | Methods: In vitro cell proliferation assays and kinase/ion channel/metabolic enzyme screening systems were used to evaluate the antitumor activity and selectivity of PKI-179 hydrochloride. Results: : 1.PKI-179 hydrochloride significantly inhibited tumor cell proliferation, with IC₅₀ values of 22 nM and 29 nM for MDA361 and PC3 cells, respectively. 2.At concentrations higher than 30 μM, PKI-179 hydrochloride showed no obvious inhibitory effect on 361 other kinases, hERG, and multiple cytochrome P450 (CYP) isoforms, but exhibited certain inhibitory activity against CYP2C8 with an IC₅₀ of 3 μM [1]. |
| In vivo | Methods: Nude mice bearing MDA-361 human breast cancer xenografts were treated with oral administration to evaluate the in vivo antitumor activity, target inhibition and tolerability of PKI-179 hydrochloride. The oral bioavailability and half-life of PKI-179 hydrochloride were determined in multiple animal models including nude mice, rats, monkeys and dogs. Results: : 1.In vivo antitumor activity and tolerability: PKI-179 hydrochloride (5–50 mg/kg, oral administration once daily for 40 days) could significantly inhibit the growth of MDA-361 human breast cancer xenografts and exhibited good tolerability in nude mice. 2.In vivo target signaling inhibition: PKI-179 hydrochloride (50 mg/kg, oral administration) effectively suppressed PI3K signaling in nude mice bearing MDA-361 tumor xenografts. 3.Oral bioavailability and half-life: PKI-179 hydrochloride displayed favorable oral bioavailability (98% in nude mice, 46% in rats, 38% in monkeys, 61% in dogs) with a long half-life (>60 minutes) [1]. |
| Molecular Weight | 525.00 |
| Formula | C25H29ClN8O3 |
| Cas No. | 1463510-35-1 |
| Smiles | Cl.O=C(NC=1C=CN=CC1)NC=2C=CC(=CC2)C=3N=C(N=C(N3)N4C5COCC4CC5)N6CCOCC6 |
| Relative Density. | no data available |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol: Slightly soluble DMF: 2.00 mg/mL (3.81 mM), Sonication is recommended. DMSO:PBS(pH 7.2) (1:3): 0.25 mg/mL (0.48 mM), Sonication is recommended. DMSO: 16.00 mg/mL (30.48 mM), Sonication is recommended. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.